Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Informa underlying revenues up 9.3pc YTD

(Sharecast News) - Publishing and events business Informa said on Tuesday that underlying revenues had grown 9.3% in the five months ended 31 May as it told investors that roughly 70% of FY target revenues had already been traded, booked or committed. Informa said B2B Live Events revenues were up 8.3% in the period, while its Academic Markets arm reported underlying revenue growth of 13.7%, and its Informa TechTarget wing posted an underlying revenue decline of roughly 5%, reflecting "continuing market softness" through the accelerated combination period.

Looking ahead, Informa said revenues of more than £2.8bn had already been traded, booked or committed for the full year through subscriptions, recurring exhibitor revenues and forward booked contracts, pacing it ahead of last year.

Informa also reaffirmed its FY underlying revenue growth guidance of over 5%, with B2B Events revenue expected to be over 7% higher year-on-year. However, it did note that further weakening of the US dollar was expected to translate to reported revenues of roughly £4.0bn and adjusted earnings growth of 10%.

Chief executive Stephen Carter said: "The commercial power of our Live B2B Event Brands and Academic Market Services is driving further strong growth for Informa.

"The Informa Growth Platform is built on leading specialist Brands, market categories in structural growth, International reach into growth economies, first-party data and world-class industry talent"

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.